|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Provision for credit losses | |||||
| Provision for inventory obsolescence | |||||
| Change in reserve for PP&E impairment | |||||
| Provision for deferred income taxes | |||||
| Share-based compensation | |||||
| Loss from disposal of property and equipment | |||||
| Unrealized foreign currency (gain)/loss, net | |||||
| Loss on extinguishment of debt | |||||
| Amortization of right-to-use asset | |||||
| Gain from write-off of liability | |||||
| Change in fair value of derivative instruments | |||||
| Change in fair value of contingent consideration | |||||
| Non-cash loss on contract termination | |||||
| Stock compensation in lieu of cash fees | |||||
| Interest capitalized for construction in progress | |||||
| Non-cash interest expense and amortization of debt discount | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventory | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued liabilities | |||||
| Operating lease liabilities | |||||
| Other liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property and equipment | |||||
| Cash used in business acquisitions, net of cash acquired | |||||
| Cash used in asset acquisitions | |||||
| Cost incurred for intangible assets | |||||
| Capital expenditures on construction in progress | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Issuance of common stock, net of underwriters’ discount and issuance costs | |||||
| Total issuance of common stock, net of underwriters’ discount and issuance costs | |||||
| Borrowings under Oaktree credit agreement, net of debt discount and issuance costs | |||||
| Repayment of Madryn debt agreement | |||||
| Repayments on finance leases | |||||
| Repayments of short term notes payable for insurance premium financing | |||||
| Proceeds from stock option exercises | |||||
| Tax payments related to shares withheld upon vesting of restricted stock | |||||
| Net cash provided by financing activities | |||||
| Effect of exchange rate changes on cash and cash equivalents | |||||
| Net (decrease)/increase in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
| Supplemental disclosures: | |||||
| Cash paid for interest | |||||
| Cash paid for income taxes | |||||
| Supplemental disclosures of non-cash investing and financing activities: | |||||
| Unpaid balance for property and equipment | |||||
| Unpaid balance for intangible assets | |||||
| Equity consideration in an asset acquisition | |||||
| Consideration payable related to asset acquisition | |||||
| Equity consideration issued in a business acquisition | |||||
| Contingent consideration payable related to a business acquisition | |||||
| Consideration payable related to a business acquisition | |||||
| Cashless option exercises | |||||
| Cashless warrant exercises | |||||
| Cash payable to settle contract termination | |||||
| Liability to issue shares to settle contract termination | |||||
| Borrowings of short term notes payable for insurance premium financing | |||||
Loading...